Most cited papers in Protein Degradation and Inhibitors
What are the most cited papers in Protein Degradation and Inhibitors?
The most cited paper in Protein Degradation and Inhibitors is "The language of covalent histone modifications" (Brian D. Strahl, C. David Allis, 2000), with 8,728 citations. Next come "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma" (5,031) and "Histone H3K27ac separates active from poised enhancers and predicts developmental state" (4,654).
Showing 50 of 100 papers. Every paper with more than 1,172 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | The language of covalent histone modifications Brian D. Strahl, C. David Allis · Nature | 2000 | 8,728 |
| 2 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma S. Vincent Rajkumar et al. · The Lancet Oncology | 26 Oct 2014 | 5,031 |
| 3 | Histone H3K27ac separates active from poised enhancers and predicts developmental state Menno P. Creyghton, Albert W. Cheng, G. Grant Welstead et al. · Proceedings of the National Academy of Sciences | 24 Nov 2010 | 4,654 |
| 4 | Selective inhibition of BET bromodomains P. Filippakopoulos et al. · Nature | 24 Sep 2010 | 4,363 |
| 5 | An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) Jürgen M. Lehmann, Linda B. Moore, Tracey A. Smith-Oliver et al. · Journal of Biological Chemistry | Jun 1995 | 3,648 |
| 6 | The Role of Chromatin during Transcription Bing Li, Michael Fionn Carey, Jerry L. Workman · Cell | Feb 2007 | 3,587 |
| 7 | MYC on the Path to Cancer Chi V. Dang · Cell | Mar 2012 | 3,481 |
| 8 | PROTAC targeted protein degraders: the past is prologue Miklós Békés, David R. Langley, Craig M. Crews · Nature Reviews Drug Discovery | 18 Jan 2022 | 3,294 |
| 9 | Histone deacetylases (HDACs): characterization of the classical HDAC family Annemieke J.M. de Ruijter, Albert H. Gennip, Huib N. Caron et al. · Biochemical Journal | 12 Mar 2003 | 3,118 |
| 10 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Shaji Kunnathu Kumar et al. · The Lancet Oncology | 26 Jul 2016 | 3,102 |
| 11 | A Strain-Promoted [3 + 2] Azide−Alkyne Cycloaddition for Covalent Modification of Biomolecules in Living Systems Nicholas J. Agard, Jennifer A. Prescher, Carolyn Ruth Bertozzi · Journal of the American Chemical Society | Nov 2004 | 3,025 |
| 12 | mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery Do‐Hyung Kim, Dos D. Sarbassov, Siraj Mahamed Ali et al. · Cell | Jul 2002 | 3,011 |
| 13 | The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases Vasily V. Ogryzko, R. Louis Schiltz, Valya R. RUSSANOVA et al. · Cell | Nov 1996 | 2,981 |
| 14 | Modes of resistance to anti-angiogenic therapy Gabriele Bergers, Douglas Hanahan · Nature reviews. Cancer | 24 Jul 2008 | 2,965 |
| 15 | Anticancer activities of histone deacetylase inhibitors Jessica E. Bolden, Melissa J. Peart, Ricky W. Johnstone · Nature Reviews Drug Discovery | Sep 2006 | 2,936 |
| 16 | Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain Andrew J. Bannister, Philip Zegerman, Janet F. Partridge et al. · Nature | Mar 2001 | 2,920 |
| 17 | BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc Jake E. Delmore et al. · Cell | Sep 2011 | 2,889 |
| 18 | A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations Sreenath V. Sharma, Diana Wing Lee, Bihua Li et al. · Cell | Apr 2010 | 2,858 |
| 19 | Coactivator condensation at super-enhancers links phase separation and gene control Benjamin R. Sabari et al. · Science | 21 Jun 2018 | 2,810 |
| 20 | The PI3K Pathway in Human Disease David A. Fruman, Honyin Chiu, Benjamin David Hopkins et al. · Cell | Aug 2017 | 2,806 |
| 21 | RING Domain E3 Ubiquitin Ligases Raymond J. Deshaies, Claudio A.P. Joazeiro · Annual Review of Biochemistry | Jun 2009 | 2,715 |
| 22 | International uniform response criteria for multiple myeloma Brian G.M. Durie et al. · Leukemia | 20 Jul 2006 | 2,662 |
| 23 | A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma Paul Gerard Guy Richardson et al. · New England Journal of Medicine | 25 Jun 2003 | 2,656 |
| 24 | Targeting cancer with small molecule kinase inhibitors Jianming Zhang, Priscilla Li-ning Yang, Nathanael S. Gray · Nature reviews. Cancer | 19 Dec 2008 | 2,601 |
| 25 | The many roles of histone deacetylases in development and physiology: implications for disease and therapy Michael Haberland, Rusty L. Montgomery, Eric N. Olson · Nature Reviews Genetics | 9 Dec 2008 | 2,568 |
| 26 | Multiple Myeloma Antonio Pierangelo Palumbo, Kenneth Carl Anderson · New England Journal of Medicine | 16 Mar 2011 | 2,360 |
| 27 | Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer Antonio González-Martı́n et al. · New England Journal of Medicine | 28 Sep 2019 | 2,318 |
| 28 | Improved survival in multiple myeloma and the impact of novel therapies Shaji Kunnathu Kumar, S. Vincent Rajkumar, Angela Dispenzieri et al. · Blood | 2 Nov 2007 | 2,266 |
| 29 | Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Saverio Minucci, Pier Giuseppe Pelicci · Nature reviews. Cancer | 2006 | 2,213 |
| 30 | Identification of a Primary Target of Thalidomide Teratogenicity Takumi Ito, Hideki Ando, Takayuki Suzuki et al. · Science | 11 Mar 2010 | 2,136 |
| 31 | Drugging the undruggable RAS: Mission Possible? Adrienne D. Cox, Stephen W. Fesik, Alec C. Kimmelman et al. · Nature Reviews Drug Discovery | 17 Oct 2014 | 2,058 |
| 32 | Erasers of Histone Acetylation: The Histone Deacetylase Enzymes Ed Seto, Minoru Yoshida · Cold Spring Harbor Perspectives in Biology | Apr 2014 | 2,048 |
| 33 | ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor Christin Tse, Alexander R. Shoemaker, Jessica Adickes et al. · Cancer Research | May 2008 | 1,999 |
| 34 | Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma Jesús F. San Miguel et al. · New England Journal of Medicine | 27 Aug 2008 | 1,913 |
| 35 | An auxin-based degron system for the rapid depletion of proteins in nonplant cells Kohei Nishimura, Tatsuo Fukagawa, Haruhiko Takisawa et al. · Nature Methods | 15 Nov 2009 | 1,907 |
| 36 | Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells Martin Göttlicher, Saverio Minucci, Ping Zhu et al. · The EMBO Journal | 17 Dec 2001 | 1,903 |
| 37 | Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells Jan Krönke, Namrata D. Udeshi, Anupama Narla et al. · Science | 29 Nov 2013 | 1,897 |
| 38 | RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia Johannes A. Zuber, Junwei Shi, Eric Wang et al. · Nature | Aug 2011 | 1,895 |
| 39 | The resurgence of covalent drugs Juswinder Singh, Russell C. Petter, Thomas A. Baillie et al. · Nature Reviews Drug Discovery | Apr 2011 | 1,881 |
| 40 | Histone deacetylases and cancer: causes and therapies Paul A. Marks, Richard A. Rifkind, Victoria M. Richon et al. · Nature reviews. Cancer | Dec 2001 | 1,866 |
| 41 | SUnSET, a nonradioactive method to monitor protein synthesis Enrico K. Schmidt, Giovanna Clavarino, Maurizio Ceppi et al. · Nature Methods | 22 Mar 2009 | 1,843 |
| 42 | Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family P. Filippakopoulos, S. Picaud, Maria Mangos et al. · Cell | Mar 2012 | 1,794 |
| 43 | Phthalimide conjugation as a strategy for in vivo target protein degradation Georg E. Winter, Dennis L. Buckley, Joshiawa Paulk et al. · Science | 21 May 2015 | 1,781 |
| 44 | High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma J. Anthony Child, Gareth John Morgan, Faith E. Davies et al. · New England Journal of Medicine | 7 May 2003 | 1,774 |
| 45 | Structure and ligand of a histone acetyltransferase bromodomain Christophe Dhalluin, Justin E. Carlson, Lei Zeng et al. · Nature | Jun 1999 | 1,733 |
| 46 | Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Michael S. Finnin, Jill R. Donigian, Alona Cohen et al. · Nature | Sep 1999 | 1,712 |
| 47 | Systematic and Quantitative Assessment of the Ubiquitin-Modified Proteome Woong Kim, Eric J. Bennett, Edward L. Huttlin et al. · Molecular Cell | 10 Sep 2011 | 1,668 |
| 48 | PEST sequences and regulation by proteolysis Martin C. RECHSTEINER, Scott W. Rogers · Trends in Biochemical Sciences | Jul 1996 | 1,640 |
| 49 | The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins Gang Lu, Richard E. Middleton, Huahang Sun et al. · Science | 29 Nov 2013 | 1,600 |
| 50 | Suppression of inflammation by a synthetic histone mimic Edwige Nicodème, Kate L. Jeffrey, Uwe Schaefer et al. · Nature | 10 Nov 2010 | 1,590 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.